Skip to search formSkip to main contentSkip to account menu

fingolimod

Known as: Fingolimodum 
National Institutes of Health

Related topics

Related topics

4 relations

Narrower (3)

FTY-720Gilenyafingolimod hydrochloride
fingolimod 0.5 MG Oral Capsule [Gilenya]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Impaired T-cell migration to the CNS under fingolimod and dimethyl fumarate
Objective: To evaluate the long-term effects of treatments used in MS on the T-cell trafficking profile. Methods: We enrolled 83… 
2017
2017
Oriental Medicine Samhwangsasim-tang Alleviates Experimental Autoimmune Encephalomyelitis by Suppressing Th1 Cell Responses and Upregulating Treg Cell Responses
Oriental medicine Samhwangsasim-tang (SHSST) has traditionally been used in East Asia to treat hypertension and its complications… 
2016
2016
Efficacy and Safety of Fingolimod in an Unselected Patient Population
Background Fingolimod is a first in class oral compound approved for the treatment of relapsing-remitting multiple sclerosis (RR… 
2016
2016
Immune-reconstitution Inflammatory Syndrome in Multiple Sclerosis Patients Treated With Natalizumab: A Series of 4 Cases.
2015
2015
Vitamin D3 and Monomethyl Fumarate Enhance Natural Killer Cell Lysis of Dendritic Cells and Ameliorate the Clinical Score in Mice Suffering from Experimental Autoimmune Encephalomyelitis
Experimental autoimmune encephalomyelitis (EAE) is a CD4+ T cell mediated inflammatory demyelinating disease that is induced in… 
Highly Cited
2014
Highly Cited
2014
Relapse Rates in Patients with Multiple Sclerosis Switching from Interferon to Fingolimod or Glatiramer Acetate: A US Claims Database Study
Background Approximately one-third of patients with multiple sclerosis (MS) are unresponsive to, or intolerant of, interferon… 
Review
2013
Review
2013
Fingolimod Therapy for Multiple Sclerosis
Abstract Because of its potent efficacy and oral route of administration, the approval of fingolimod as treatment for relapsing… 
Review
2011
Review
2011
Fingolimod for the treatment of relapsing multiple sclerosis
Fingolimod 0.5 mg (Gilenya™, Novartis Pharmaceuticals Corporation, FL, USA) is the first once-daily oral therapy approved for… 
Review
2011
Review
2011
Fingolimod for the treatment of relapsing multiple sclerosis
Fingolimod is the first oral agent approved in the USA for the treatment of relapsing forms of multiple sclerosis. Fingolimod is… 
Review
2007
Review
2007
FTY720, an immunomodulatory sphingolipid mimetic: translation of a novel mechanism into clinical benefit in multiple sclerosis
FTY720 (fingolimod; 2-amino-2[2-(4-octylphenyl)ethyl]-1,3-propanediol, Novartis) is the prototype of a new generation of… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)